Equities
  • Price (CHF)146.70
  • Today's Change-1.70 / -1.15%
  • Shares traded549.92k
  • 1 Year change+23.76%
  • Beta--
Data delayed at least 15 minutes, as of Feb 06 2026 16:31 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Galderma Group AG is a Switzerland based holding Company, specializing in dermatological treatments and skin care products. The Company, throw its subsidiaries, operates a portfolio of carious self-care brands focusing primarily on dermatological solutions, through its subsidiaries. production within the portfolio include neuromodulators, fillers. and biostimulators. these products are designed to relax winkles via injection, fill wrinkles in a specific location via injection and stimulate the body's cells to function optimally. The production process, for the various products primarily takes place in house, form research and development to manufacturing. In addition, including education, scientific engagements, and other services are offered.

  • Revenue in CHF (TTM)3.64bn
  • Net income in CHF293.21m
  • Incorporated2022
  • Employees6.55k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Beiersdorf AG9.04bn808.53m22.97bn22.93k26.172.6920.022.543.953.9544.1438.450.74792.674.27432,758.506.826.349.828.9158.5757.399.118.611.36--0.036825.744.275.1823.914.906.437.39
Galderma Group AG3.64bn293.21m34.80bn6.55k118.645.7365.309.561.231.2315.3025.530.36853.155.29--2.97--3.40--69.21--8.06--0.80463.480.2681--7.86--503.85------
Reckitt Benckiser Group Plc14.77bn1.32bn43.58bn37.90k33.736.6124.092.951.901.8821.129.680.54813.426.48368,944.604.924.587.136.3860.8959.378.979.280.37129.510.5939101.47-3.001.98-12.48--0.97412.97
Unilever plc54.81bn5.09bn120.60bn120.04k23.977.3916.502.202.182.1823.467.090.7671--7.62432,324.807.919.3612.3614.44--42.6410.3112.150.545426.610.616469.081.943.17-11.450.41965.251.17
Data as of Feb 06 2026. Currency figures normalised to Galderma Group AG's reporting currency: Swiss Franc CHF

Institutional shareholders

19.06%Per cent of shares held by top holders
HolderShares% Held
UBS Asset Management Switzerland AGas of 24 Dec 202512.70m5.34%
Wellington Management Co. LLPas of 23 Aug 20257.14m3.00%
The Vanguard Group, Inc.as of 07 Jan 20266.45m2.71%
Schroder Investment Management Ltd.as of 31 Dec 20253.20m1.35%
Z�rcher Kantonalbank (Investment Management)as of 31 Dec 20252.99m1.26%
Norges Bank Investment Managementas of 30 Jun 20252.98m1.25%
BlackRock Fund Advisorsas of 09 Jan 20262.88m1.21%
Jennison Associates LLCas of 08 Jan 20262.52m1.06%
Fidelity Management & Research Co. LLCas of 30 Nov 20252.51m1.06%
RBC Global Asset Management (UK) Ltd.as of 31 Dec 20251.98m0.83%
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.